Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased ...

As the Nasdaq reaches record highs driven by surges in chip stocks and Apple, while the S&P 500 shows signs of losing momentum, investors are keenly observing market fluctuations influenced by tariff ...

Get insights from Ligand Pharmaceuticals' Q2 2025 earnings—57% royalty revenue growth, raised guidance, and key partnerships driving long-term growth.

Ligand Pharmaceuticals (NASDAQ:LGND), a biopharma company known for earning royalties from a broad portfolio of drugs, announced results for the second quarter of 2025 on August 7 ...

Orchestra BioMed reported that it has secured over $111 million in financing through a series of transactions and ...

Orchestra BioMed announced today that it completed strategic transactions and equity offerings worth an expected $111.2 ...

This study presents a valuable finding about how receptor-ligand binding pathways with multi-site phosphorylation can show non-monotonic responses to increasing ligand affinity and to kinase activity.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, ...

Research indicates that high-dose vitamin D improves bone health in very low birth weight preterm infants, highlighting its ...

Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra's AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement • Medtronic to inve ...

ABCL-575’s predicted dosing schedule of every six months is enabled by a "human half-life of approximately 67 days," as ...